K Number
K112650
Device Name
CONNEXALL SUITE OF SOFTWARE PRODUCTS
Date Cleared
2012-02-01

(142 days)

Product Code
Regulation Number
870.2300
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdparty
Intended Use
The intended use of the Connexall Suite of Software Products is to provide an interface with clinical systems to forward information associated to the particular event to the designated display device(s). For medical, near real time alarms, the Connexall Suite of Software Products is intended to serve as a parallel, redundant, forwarding mechanism to inform healthcare professionals of particular medical related events. The Connexall Suite of Software Products does not alter the behavior of the primary medical devices and associated alarm annunciations. The display device provides a visual, and/or audio and/or vibrating mechanism upon receipt of the alert. The Connexall Suite of Software Products is intended for use as a secondary alarm. It does not replace the primary alarm function on the monitor.
Device Description
The Connexall USA. Inc. (Connexall) Suite of Software Products (Software) is an on-site messaging integration solution which forwards patient monitor status and alarm information to the user via display devices provided by third-party mobile device companies. Users receive interactive, time-critical information from patient monitoring devices directly via their display devices as text, alarms or data. Connexall Software allows users to be aware of their patients' status and alarm conditions when they are away from the patient and patient monitoring system. Connexall Software is a client/server application designed to run under any Microsoft Windows 32-bit operating system. At the core of the application is the Notification Server. The Notification Server includes the database application, system administration, licensing, and the resources to manage the near-real-time event processing and dispatching. The Connexall Suite of Software Products is offered in four (4) configurations. These configurations include: - Connexall Enterprise; -. - . Connexall Pro: - Connexall Care; and . - Connexall LITE. .
More Information

Not Found

No
The description focuses on event forwarding and messaging, with no mention of AI/ML terms or functionalities like learning, prediction, or complex data analysis beyond simple routing.

No
This device is a software product that serves as a secondary alarm and forwarding mechanism for medical events, not a device that directly provides therapy.

No

The device is described as a "messaging integration solution" and a "secondary alarm" system that forwards information and alarms from primary medical devices to healthcare professionals. It does not analyze patient data or determine medical conditions itself, which are typical functions of a diagnostic device.

Yes

The device description explicitly states "The Connexall USA. Inc. (Connexall) Suite of Software Products (Software) is an on-site messaging integration solution..." and details its software components and configurations. While it interacts with third-party display devices, the core medical device functionality described is solely within the software.

Based on the provided text, the Connexall Suite of Software Products is not an IVD (In Vitro Diagnostic) device.

Here's why:

  • IVD Definition: In Vitro Diagnostic devices are used to examine specimens taken from the human body (like blood, urine, tissue) to provide information for diagnosis, monitoring, or screening.
  • Connexall's Function: The Connexall software's intended use is to interface with clinical systems and forward information (specifically near real-time alarms from medical devices) to display devices for healthcare professionals. It acts as a communication and notification system.
  • No Specimen Analysis: The description does not mention the software analyzing any biological specimens or performing any tests on samples taken from the body. Its function is solely related to relaying information from other medical devices.

Therefore, the Connexall Suite of Software Products falls outside the scope of an In Vitro Diagnostic device.

N/A

Intended Use / Indications for Use

The intended use of the Connexall Suite of Software Products is to provide an interface with clinical systems to forward information associated to the particular event to the designated display device(s).

For medical, near real time alarms, the Connexall Suite of Software Products is intended to serve as a parallel, redundant, forwarding mechanism to inform healthcare professionals of particular medical related events. The Connexall Suite of Software Products does not alter the behavior of the primary medical devices and associated alarm annunciations. The display device provides a visual, and/or audio and/or vibrating mechanism upon receipt of the alert.

The Connexall Suite of Software Products is intended for use as a secondary alarm. It does not replace the primary alarm function on the monitor.

Product codes (comma separated list FDA assigned to the subject device)

MSX

Device Description

The Connexall USA. Inc. (Connexall) Suite of Software Products (Software) is an on-site messaging integration solution which forwards patient monitor status and alarm information to the user via display devices provided by third-party mobile device companies. Users receive interactive, time-critical information from patient monitoring devices directly via their display devices as text, alarms or data. Connexall Software allows users to be aware of their patients' status and alarm conditions when they are away from the patient and patient monitoring system.

Connexall Software is a client/server application designed to run under any Microsoft Windows 32-bit operating system. At the core of the application is the Notification Server. The Notification Server includes the database application, system administration, licensing, and the resources to manage the near-real-time event processing and dispatching.

The Connexall Suite of Software Products is offered in four (4) configurations. These configurations include:

  • Connexall Enterprise; -.
  • . Connexall Pro:
  • Connexall Care; and .
  • Connexall LITE. .

Mentions image processing

Not Found

Mentions AI, DNN, or ML

Not Found

Input Imaging Modality

Not Found

Anatomical Site

Not Found

Indicated Patient Age Range

Not Found

Intended User / Care Setting

healthcare professionals

Description of the training set, sample size, data source, and annotation protocol

Not Found

Description of the test set, sample size, data source, and annotation protocol

Not Found

Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)

Software Testing: The Connexall Suite of Software Products was designed and developed according to a robust software development process, and was rigorously verified and validated. Test results indicated that the Connexall Suite of Software Products complies with its predetermined specifications.

Conclusion: Verification and validation activities were conducted to establish the performance and safety characteristics of the Connexall Suite of Software Products. The results of these activities demonstrate that the Connexall Suite of Software Products is safe and effective when used in accordance with its intended use and labeling. Therefore, the Connexall Suite of Software Products is considered substantially equivalent to the predicate device.

Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)

Not Found

Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.

K102974

Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.

Not Found

Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).

Not Found

§ 870.2300 Cardiac monitor (including cardiotachometer and rate alarm).

(a)
Identification. A cardiac monitor (including cardiotachometer and rate alarm) is a device used to measure the heart rate from an analog signal produced by an electrocardiograph, vectorcardiograph, or blood pressure monitor. This device may sound an alarm when the heart rate falls outside preset upper and lower limits.(b)
Classification. Class II (performance standards).

0

K112650 P1/3

FEB - 1 2012

510(k) Summary

Submission Date:09 September 2011
Submitter:Connexall USA, Inc.
5540 Central Avenue, Suite 220
Boulder, CO 80301
Submitter Contact:Mr. John Elms
Connexall USA, Inc.
5540 Central Avenue, Suite 220
Boulder, CO 80301
+1 (720) 279-8707
jelms@connexall.com)
Official Contact:Mr. Thomas Kroenke
Speed To Market, Inc.
PO Box 3018
Nederland, CO 80466
+1 (303) 956-4232
tkroenke@speedtomarket.net
Manufacturing Site:Globestar Systems Inc.
7 Kodiak Crescent, Suite 100
Toronto, Ontario, Canada M3J 3E5
Trade Name:Connexall Suite of Software Products
Common Name:Network and Communication Middleware
Classification Name:System, Network And Communication, Physiological Monitors
Classification
Regulation:21 CFR §870.2300
Product Code:MSX
Substantially
Equivalent Devices:Connexall ModelPredicate 510(k)
NumberPredicate Manufacturer
and Model
Connexall Suite of
Software ProductsK102974Philips Medical Systems
Philips Emergin Event
Management System

Page 1 of 3

:

,

1

Image /page/1/Picture/0 description: The image shows handwritten text that appears to be a combination of alphanumeric characters. The text is "K112650 P2/3". The characters are written in black ink on a white background and appear to be part of a label or code.

Device Description: The Connexall USA. Inc. (Connexall) Suite of Software Products (Software) is an on-site messaging integration solution which forwards patient monitor status and alarm information to the user via display devices provided by third-party mobile device companies. Users receive interactive, time-critical information from patient monitoring devices directly via their display devices as text, alarms or data. Connexall Software allows users to be aware of their patients' status and alarm conditions when they are away from the patient and patient monitoring system.

Connexall Software is a client/server application designed to run under any Microsoft Windows 32-bit operating system. At the core of the application is the Notification Server. The Notification Server includes the database application, system administration, licensing, and the resources to manage the near-real-time event processing and dispatching.

The Connexall Suite of Software Products is offered in four (4) configurations. These configurations include:

  • Connexall Enterprise; -.
  • . Connexall Pro:
  • Connexall Care; and .
  • Connexall LITE. .

Intended Use:

The intended use of the Connexall Suite of Software Products is to provide an interface with clinical systems to forward information associated to the particular event to the designated display device(s).

For medical, near real time alarms, the Connexall Suite of Software Products is intended to serve as a parallel, redundant, forwarding mechanism to inform healthcare professionals of particular medical related events. The Connexall Suite of Software Products does not alter the behavior of the primary medical devices and associated alarm annunciations. The display device provides a visual, and/or audio and/or vibrating mechanism upon receipt of the alert.

The Connexall Suite of Software Products is intended for use as a secondary alarm. It does not replace the primary alarm function on the monitor.

Technology Comparison: The Connexall Suite of Software Products employs the same or similar technological characteristics as the predicate device.

2

Image /page/2/Picture/0 description: The image shows a handwritten text string. The string appears to be an alphanumeric code or identifier. The text reads 'KI12650 P3/3' and is written in black ink on a white background.

Performance Testing:

| Software Testing | The Connexall Suite of Software Products was designed and developed
according to a robust software development process, and was rigorously
verified and validated. |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| | Test results indicated that the Connexall Suite of Software Products
complies with its predetermined specifications. |
| Conclusion | Verification and validation activities were conducted to establish the
performance and safety characteristics of the Connexall Suite of
Software Products. The results of these activities demonstrate that the
Connexall Suite of Software Products is safe and effective when used in
accordance with its intended use and labeling. |
| | Therefore, the Connexall Suite of Software Products is considered
substantially equivalent to the predicate device. |

.

3

Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002

FEB - 1 2012

Connexall USA, Inc. c/o Mr. Thomas Kroenke Speed To Market, Inc. P.O. Box 3018 Nederland, CO 80466

Re: K112650

Trade/Device Name: Connexall Suite of Software Products Regulation Number: 21 CFR 876.2300 Regulation Name: Cardiac Monitor (including cardiotachometer and rate alarm) Regulatory Class: Class II (two) Product Codes: MSX Dated: January 30, 2012 Received: January 30, 2012

Dear Mr. Kroenke:

We have reviewed your Section 510(k) premarket notification of intent to market the device we nave reviewed your becamed the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate for use stated in the encreated of the enactment date of the Medical Device Amendments, or to eonimered processified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The r ou may, merers, mans of the Act include requirements for annual registration, listing of general controls provisions gractice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it your device is elaborned (600 a00 as) as a stime major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

4

Page 2 – Mr. Thomas Kroenke

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.

Sincerely yours,

Bram D. Zuckerman, M.D.

Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

5

Indications for Use

510(k) Number (if known):K
Device Name:Connexall Suite of Software Products
Indications for Use:The intended use of the Connexall Suite of Software Products is to provide an interface with clinical systems to forward information associated to the particular event to the designated display device(s).
For medical, near real time alarms, the Connexall Suite of Software Products is intended to serve as a parallel, redundant, forwarding mechanism to inform healthcare professionals of particular medical related events. The Connexall Suite of Software Products does not alter the behavior of the primary medical devices and associated alarm annunciations. The display device provides a visual, and/or audio and/or vibrating mechanism upon receipt of the alert.
The Connexall Suite of Software Products is intended for use as a secondary alarm. It does not replace the primary alarm function on the monitor.

| Prescription Use

(Part 21 CFR 801 Subpart D)X
----------------------------------------------------

AND/OR

| Over-The-Counter Use

(21 CFR 807 Subpart C)
--------------------------------------------------

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF
NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

(Division Sign-Off)
Division of Cardiovascular Devices
510(k) NumberK112650
------------------------

・・

Page 1 of 1

:

.

·

: